Natural Product (NP) Details
| General Information of the NP (ID: NP8902) | |||||
|---|---|---|---|---|---|
| Name |
Ursolic acid
|
||||
| Synonyms |
Prunol; Malol; Urson; 77-52-1; 3beta-Hydroxyurs-12-en-28-oic acid; (3beta)-3-Hydroxyurs-12-en-28-oic acid; 3beta-Hydroxy-12-ursen-28-ic acid; UNII-P3M2575F3F; CHEBI:9908; CCRIS 7123; EINECS 201-034-0; CHEMBL169; Merotaine; AI3-03109; NSC4060; P3M2575F3F; NSC-4060; Urs-12-en-28-oic acid, 3-hydroxy-, (3beta)-; HNMR; .beta.-Ursolic acid; NSC 4060; NSC 167406
Click to Show/Hide
|
||||
| Species Origin | Potentilla indica ... | Click to Show/Hide | |||
| Potentilla indica | |||||
| Chamaenerion angustifolium | |||||
| Callicarpa dichotoma | |||||
| Eriobotrya japonica | |||||
| Anredera cordifolia | |||||
| Chrysanthemum indicum | |||||
| Syzygium nervosum | |||||
| Acanthus ilicifolius | |||||
| Emilia sonchifolia | |||||
| Elaeagnus pungens | |||||
| Callicarpa formosana | |||||
| Clinopodium gracile | |||||
| Callicarpa cathayana | |||||
| Disease | Rotavirus infection [ICD-11: 1A22] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C30H48O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C)C(=O)O
|
||||
| InChI |
1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1
|
||||
| InChIKey |
WCGUUGGRBIKTOS-GPOJBZKASA-N
|
||||
| CAS Number |
CAS 77-52-1
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Capecitabine | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ICAM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PECAM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | |||
| In-vivo Model | HCT116 cells (1.5*106 cells) in 50 mL of PBS were injected into the cecum of athymic nu/nu mice (4 weeks old) using a 30-gauge needle. | |||||
| Experimental
Result(s) |
Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis. | |||||
| Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | IKKA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | |||
| RKO | CVCL_0504 | Colon carcinoma | Homo sapiens | |||
| In-vivo Model | SW620 cells (1*107) were injected subcutaneously into the right flank area of 6-8-week-old female nude mice. | |||||
| Experimental
Result(s) |
Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin. | |||||
| Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ICAM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| MDA-Panc-28 | CVCL_3917 | Pancreatic adenocarcinoma | Homo sapiens | |||
| In-vivo Model | A small incision was made in the left abdominal flank of male athymic nu/nu mice, and luciferase transfected Panc-28 cells (1*106) in 50L PBS were injected into the subcapsular region of the pancreas with a 27-gauge needle. | |||||
| Experimental
Result(s) |
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Disruption | Glycolysis | ||||
| Disruption | TCA cycle | |||||
| Disruption | Glutamine metabolism | |||||
| Disruption | Synthesis of amino acids | |||||
| Down-regulation | P-gp efflux | |||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids. | |||||
| β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | GABPA | Molecule Info | ||
| Down-regulation | Expression | GSTK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NQO1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G0/G1 phase | ||||
| Up-regulation | ROS generation | |||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway. | |||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MGMT | Molecule Info | ||
| In-vitro Model | LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | ||
| LN-18 | CVCL_0392 | Glioblastoma | Homo sapiens | |||
| T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
| In-vivo Model | LN18 cells (5*106/mouse) were subcutaneously injected into the left hind flank of each female BALB/c mouse. | |||||
| Experimental
Result(s) |
Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) | Molecule Info | [8] | |
| Herpes simplex virus DNA polymerase UL30 (HSV UL30) | Molecule Info | [9] | ||
| Myophosphorylase (PYGM) | Molecule Info | [10] | ||
| Phospholipase A2 (PLA2G1B) | Molecule Info | [11] | ||
| BioCyc | Phospholipases | Click to Show/Hide | ||
| 2 | Glycogenolysis | |||
| KEGG Pathway | Steroid hormone biosynthesis | Click to Show/Hide | ||
| 2 | Metabolism of xenobiotics by cytochrome P450 | |||
| 3 | Metabolic pathways | |||
| 4 | Chemical carcinogenesis | |||
| 5 | Glycerophospholipid metabolism | |||
| 6 | Ether lipid metabolism | |||
| 7 | Arachidonic acid metabolism | |||
| 8 | Linoleic acid metabolism | |||
| 9 | alpha-Linolenic acid metabolism | |||
| 10 | Ras signaling pathway | |||
| 11 | Vascular smooth muscle contraction | |||
| 12 | Pancreatic secretion | |||
| 13 | Fat digestion and absorption | |||
| 14 | Starch and sucrose metabolism | |||
| 15 | Insulin signaling pathway | |||
| 16 | Glucagon signaling pathway | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | FSH Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | Click to Show/Hide | ||
| Pathwhiz Pathway | Steroidogenesis | Click to Show/Hide | ||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
| Reactome | Glucocorticoid biosynthesis | Click to Show/Hide | ||
| 2 | Acyl chain remodelling of PC | |||
| 3 | Acyl chain remodelling of PE | |||
| 4 | Acyl chain remodelling of PI | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
| 2 | Metabolism of steroid hormones and vitamin D | |||
| 3 | Glucocorticoid & Mineralcorticoid Metabolism | |||
| 4 | Glycerophospholipid biosynthesis | |||
| 5 | Glycogen Metabolism | |||
| 6 | Metabolism of carbohydrates | |||
